MBMarco Ballotari

Marco Ballotari

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marco Ballotari has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Postmortem case series of Δ8- and Δ9-tetrahydrocannabinol in blood and urine

    by Munchelou M. Gomonit, Marco Ballotari, Michael T. Truver, Sara C. Brogan, Jennifer L. Hoyer, Bruce A. Goldberger, Chris W. Chronister

    The growing popularity of delta-8-tetrahydrocannabinol (Δ8-THC) products has introduced new analytical and interpretive challenges for forensic toxicology laboratories. While delta-9-tetrahydrocannabinol (Δ9-THC) and its metabolites have been extensively characterized in postmortem casework, comparable data for Δ8-THC remain scarce. This study presents a validated LC-MS/MS method for the quantitation of Δ8-THC, Δ9-THC, and their primary metabolites in postmortem blood. Sample preparation employed liquid-liquid extraction using water acidified with 10% acetic acid, followed by extraction with hexane: ethyl acetate (90:10, v/v). The validated method was subsequently applied to a selected subset of authentic postmortem blood samples (n = 107) previously identified to contain Δ8- and/or Δ9-THC-COOH by GC-MS urine testing. Among these cannabinoid-positive urine cases, 39.3% were positive in blood for both Δ8- and Δ9-THC and their metabolites, whereas 25.2% and 14.0% were positive for only Δ8-THC and Δ9-THC-related analytes, respectively. Δ8-THC blood concentrations ranged from 1.0 to 90.4 ng/mL, and Δ8-THC-COOH concentrations ranged from 5.1 to 1484 ng/mL. Additionally, 11-OH-Δ8-THC was measured in 11.2% of cases and consistently co-occurred with Δ8-THC and Δ8-THC-COOH. These findings provide descriptive postmortem concentration data for Δ8-THC and highlight the importance of adequate chromatographic resolution of THC isomers. Importantly, we also underscore the interpretive challenges of polycannabinoid findings in postmortem casework, where detection of Δ8-THC, Δ9-THC, and/or their metabolites should be interpreted as evidence of cannabinoid exposure, and not as definitive evidence of impairment, intoxication, or contribution to death without additional case context.

  • Prevalence of p -fluorofentanyl and xylazine in postmortem fentanyl casework

    by Marco Ballotari, Michael T Truver, Jennifer L Hoyer, Bruce A Goldberger, Chris W Chronister

    In the United States (U.S.), fentanyl remains the leading drug associated with opioid-related deaths. Many analogs of fentanyl have been identified and linked to the opioid overdose epidemic. After core-structure scheduling of illicitly manufactured fentanyl (IMF) and related products, para-fluorofentanyl (p-FF) reemerged with varied prevalence in the U.S. Xylazine also emerged as a cutting agent in IMF. The aim of this study was to describe the prevalence and trend use patterns of fentanyl, p-FF, and xylazine in a case series from 2021 to 2023 in the state of Florida. A three-year retrospective analysis of data was conducted. A total of 8121 cases were submitted for analysis over the period of study. Among them, 1530 cases (18.8%) tested positive for fentanyl in one or more of the specimens submitted for these cases. The age of the decedents ranged 16–85 years, with the majority being White males. The concentration range of fentanyl in the blood specimens (n = 1358) analyzed was 2.5–579 ng/mL. p-FF was detected with fentanyl in 164 postmortem blood specimens with a concentration range of 2.5–65 ng/mL. Xylazine was identified in the urine of 391 decedents. The combination of fentanyl, p-FF, and xylazine was detected in 70 cases. When fentanyl co-occurred with both xylazine and p-FF, it was primarily observed with benzodiazepines, cocaine, methamphetamine, and other opioids. This study aimed to provide a better understanding of the fentanyl analog and adulterant prevalence in Florida.

  • Δ 8 ‐tetrahydrocannabinol, Δ 9 ‐tetrahydrocannabinol, and cannabidiol carboxylic acid metabolites in authentic meconium samples

    by Marco Ballotari, Michael T. Truver, Chris W. Chronister, Jennifer L. Hoyer, Kay Roussos‐Ross, Amie J. Goodin, Sarah H. Bartock, Tiara Evans, Wen Dui, Bruce A. Goldberger

    The consumption of cannabis‐related products during pregnancy is increasing. Marijuana (cannabis) use during pregnancy, whether for nonmedical or medical purposes to relieve of pregnancy‐related symptoms and discomfort, can lead to potential adverse clinical and neurodevelopmental outcomes for the developing fetus. Testing conventional matrices, such as blood and urine, provides information regarding the recent intake of drugs, whereas analysis of alternative specimens, such as meconium, provides information regarding maternal use and potential in utero exposure during the third trimester of pregnancy. In this study, meconium samples ( n = 19) were obtained from neonates at birth delivered at the University of Florida (UF). All the mothers participating in the study completed a questionnaire regarding cannabis and cannabidiol (CBD) use during pregnancy. Maternal urine samples were also collected during each trimester of pregnancy and at delivery. 11‐nor‐Δ 9 ‐tetrahydrocannabinol‐9‐carboxylic acid (Δ 9 ‐THC‐COOH), 11‐nor‐Δ 8 ‐tetrahydrocannabinol‐9‐carboxylic acid (Δ 8 ‐THC‐COOH) and 7‐carboxy cannabidiol (7‐COOH‐CBD) were quantitated in the meconium samples utilizing liquid chromatography‐tandem mass spectrometry (LC–MS/MS). The most frequently identified analyte was Δ 9 ‐THC‐COOH (median concentration: 113 ng/g) which was quantitated in the meconium samples ( n = 12) of neonates born to mothers who self‐reported cannabis use during the third trimester. Δ 8 ‐THC‐COOH was observed in five of the Δ 9 ‐THC‐COOH positive samples (median concentration: 15.7 ng/g). Meconium of neonates born to mothers who did not self‐report a history of cannabis use (control subjects) was negative for Δ 8 ‐THC‐COOH and Δ 9 ‐THC‐COOH. These data support further study of drug use patterns during pregnancy to focus on the clinical consequences of use during the perinatal period.

  • Prevalence of N,N-Dimethylpentylone in forensic toxicology casework: A retrospective study and trends in the state of Florida

    by Marco Ballotari, Michael T. Truver, Elisa N. Shoff, Nicholas B. Tiscione, Kristin W. Kahl, Diane M. Moore, Lisa J. Reidy, Bruce A. Goldberger, Chris W. Chronister


  • Analysis of cannabinoids and semi-synthetic cannabinoids in authentic breastmilk samples by liquid chromatography–tandem mass spectrometry

    by Marco Ballotari, Michael T Truver, Nayana A Sojin, Rhea Parimoo, Lauren A Agliano, Jennifer L Hoyer, Amie J Goodin, Deepthi S Varma, Chris W Chronister, Kay Roussos-Ross, et al.

    Marijuana (cannabis) is generally considered the most frequently misused substance during pregnancy. The prevalence in the use of either medical or non-medical marijuana for relief of pregnancy-related symptoms is increasing, as well as the use of cannabis-related products containing cannabidiol (CBD) and semi-synthetic cannabinoids (SSCs). Δ9-tetrahydrocannabinol (THC) and CBD are highly lipophilic substances and will readily pass into breastmilk upon ingestion. The solubility of THC and CBD in lipids poses significant analytical challenges in extracting and identifying these substances in breastmilk. The aim of this study was to develop a new and sensitive assay utilizing liquid chromatography–tandem mass spectrometry (LC–MS/MS) for the detection of cannabinoids in breastmilk. The method was optimized to quantitate Δ8-THC, Δ9–THC, cannabigerol (CBG), CBD, and cannabidiolic acid (CBDA) and validated with the guidance of the American Academy of Forensic Sciences Standards Board (ASB) Standard 036. The assay was then used to analyze breastmilk samples (N = 57) collected postpartum from female patients enrolled in a study assessing use behaviors of medical marijuana, non-medical marijuana, and CBD. All analytes passed validation criteria. Calibration curves for all analytes ranged 0.5–400 ng/mL, with the LOD and LLOQ of the method set at the lowest calibrator concentration. Δ9-THC was quantitated in 19 samples (33.3%) with a concentration range of 0.5–291 ng/mL. Δ8-THC was detected in one sample (1.8%) at 0.8 ng/mL, while CBD was observed in 3 samples at a concentration <LLOQ, and quantitated in only one sample (1.8%) also at a concentration of 0.8 ng/mL. CBG was detected in 7 samples (12.2%) with a concentration range of 0.6–12.9 ng/mL, and at a concentration <LLOQ in 12 samples. This study presents a sensitive method for the analysis of cannabinoids in breastmilk to support the follow-up assessments of marijuana and CBD use during pregnancy and postpartum.


  • Identifying bromazolam, etizolam, and flualprazolam in blood using gas chromatography–mass spectrometry

    by Marco Ballotari, Michael T. Truver, Devin C. Baer, Sara C. Brogan, Jennifer L. Hoyer, Michele M. Crosby, Bruce A. Goldberger, Chris W. Chronister

    Designer benzodiazepines are a commonly misused class of novel psychoactive substances (NPS) that present challenges for forensic toxicology laboratories and public health. Due to the difficulty in detection by routine toxicology methods, it is important to enhance the analytical methods for the identification and quantitation of designer benzodiazepines. The aim of this study was to identify and quantify designer benzodiazepines using gas chromatography coupled with mass spectrometry (GC‐MS) in postmortem blood specimens. A method originally validated to identify and quantitate alprazolam was modified to quantitate flualprazolam, etizolam, and bromazolam, as well as identify adinazolam and 4′‐chloro‐deschloroalprazolam. The method was subsequently used to analyze postmortem specimens (n = 35) from Medical Examiner Districts (n = 4) in Florida that screened positive for one or more designer benzodiazepines from February 2022 to December 2023. Among the screened samples, 21 tested positive for one or more designer benzodiazepines in the postmortem blood; 1 was positive for etizolam (90 ng/mL) and flualprazolam (<5.0 ng/mL), while 20 were positive for bromazolam. Bromazolam was the most frequently detected designer benzodiazepine, with a concentration range of 5.9–352 ng/mL (mean: 59.1 ng/mL; median: 28.5 ng/mL) for 18 decedents and <5.0 ng/mL for two decedents. Polydrug use was confirmed in all decedents. The most prevalent drugs found with bromazolam in the blood were fentanyl, methamphetamine and/or amphetamine, and cocaine. The optimized GC‐MS method provides a way to identify and quantitate designer benzodiazepines in postmortem blood and to also qualitatively monitor two newer designer benzodiazepines: 4′‐chloro‐deschloroalprazolam and adinazolam.


  • Quantitative analysis of Δ8- and Δ9-tetrahydrocannabinol metabolites and isomers: a rapid assay in urine by LC-MS/MS

    by Marco Ballotari, Michael T. Truver, Nayana A. Sojin, Lauren A. Agliano, Rhea Parimoo, Jennifer L. Hoyer, Amie J. Goodin, Deepthi S. Varma, Chris W. Chronister, Kay Roussos-Ross, et al.

    An increasing number of cannabis-related products have become available and entered the market, particularly those containing cannabidiol (CBD) and Δ8-tetrahydrocannabinol (Δ8-THC). Analytical methods for cannabinoids in urine have been described extensively in the literature. However, methods providing good resolution for distinguishing interferences from THC positional isomers are needed. The aim of this project was to develop and validate a liquid chromatography with tandem mass spectrometry (LC-MS/MS) method to quantitate a broad panel of cannabinoids in authentic urine specimens. The method was optimized to quantitate Δ8-THC and Δ9-THC, 11-OH-Δ8-THC and 11-OH-Δ9-THC, Δ8-THC-COOH and Δ9-THC-COOH, CBD, 7-COOH-CBD, CBG, and CBN, and validated with the guidance of the American Academy of Forensic Sciences Standards Board (ASB) Standard 036. The validated assay was then used to evaluate urine samples collected over various time points from female patients (N = 69) enrolled in a study assessing prevalence of marijuana/CBD use during pregnancy from November 2022 to May 2024. Δ8- and Δ9- isomers were chromatographically resolved and successfully separated. For all analytes, the lower limit of quantitation (LLOQ) was determined to be 10 ng/mL, and the upper limit of quantitation (ULOQ) was 1000 ng/mL. In the authentic samples, the most frequently detected analyte was Δ9-THC-COOH, with a median concentration of 278 ng/mL (n = 38). Δ9-THC and 11-OH-Δ9-THC were detected with a median concentration of 42.4 ng/mL (n = 5) and 65.7 ng/mL (n = 34), respectively. Δ8-THC-COOH was detected in n = 3 specimens, with a median concentration of 25.5 ng/mL. The study provided a rapid assay for the analysis of cannabinoids in urine. Graphical Abstract


  • A postmortem case report involving fentanyl, desalkylgidazepam, and bromazolam

    by Marco Ballotari, Michael T Truver, Leena R Dhoble, Amy M Kinsey, Jennifer L Hoyer, Chris W Chronister, Bruce A Goldberger

    The emergence of new psychoactive substances (NPS) and the number of new chemically diverse substances in the global illicit drug market have significantly increased over the last few years. Designer benzodiazepines are some of the most misused NPS worldwide, contributing to both nonfatal and fatal drug overdose cases. The use of desalkylgidazepam and bromazolam has recently emerged, and their prevalence has been internationally reported. In this study, we quantified desalkylgidazepam and bromazolam using gas chromatography coupled with mass spectrometry (GC–MS) in the postmortem specimens of a subject found deceased due to suspected drug overdose. A 24-year-old white male with a history of drug use was found unresponsive and not breathing in his home with drug paraphernalia nearby. A yellow powdery substance and prescription tablets were also found at the scene. The GC–MS analysis of the postmortem blood and urine samples confirmed the presence of fentanyl, desalkylgidazepam, and bromazolam. The desalkylgidazepam concentration was 1100 ng/mL in the blood, which was higher than previous reports in the literature, and estimated to be 89 ng/mL in the urine. The bromazolam concentration was 352 ng/mL in the blood and estimated to be 398 ng/mL in the urine. Additionally, fentanyl was detected in the blood (11 ng/mL), and fentanyl, norfentanyl, and gabapentin were detected in the urine. The present study aims to provide the toxicological community with information regarding a fit-for-purpose analysis of two NPS benzodiazepines.


  • Open Access

    Development of a new ultra‐high‐performance liquid chromatography–tandem mass spectrometry method for the determination of digoxin and digitoxin in plasma: Comparison with a clinical immunoassay

    by Marco Ballotari, Francesco Taus, Giulia Tolle, Elisa Danese, Romolo M. Dorizzi, Franco Tagliaro, Rossella Gottardo

    Cardiac glycosides digoxin and digitoxin are used in therapy for the treatment of congestive heart failure. Moreover, these compounds can be responsible for intoxication cases caused by fortuitous ingestion of leaves of Digitalis. Due to the narrow therapeutic range of these drugs, therapeutic drug monitoring is recommended in the clinical practice. In this context, immunoassays‐based methods are generally employed but digoxin‐ and digitoxin‐like compounds can interfere with the analysis. The aim of this study was to develop and validate an original UPLC–MS/MS method for the determination of digoxin and digitoxin in plasma. The method shows adequate sensitivity and selectivity with acceptable matrix effects and very good linearity, accuracy, precision, and recovery. A simple liquid–liquid extraction procedure was used for sample clean‐up. The method was applied for the analysis of n = 220 plasma samples collected in two different clinical chemistry laboratories and previously tested by the same immunoassay. The statistical comparison showed a relevant negative bias of the UPLC–MS/MS method versus the immunoassay. These results are consistent with an immunoassay overestimation of digoxin plasmatic levels due to cross‐reaction events with endogenous digoxin‐like substances.